Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados

Escuín, Julio Sánchez de Cos; Vicente, Carlos Disdier; Peñafiel, Jaime; Miranda, José; González, M. Agustín Sojo; Jiménez, J.F. Masa

doi:10.1016/s0300-2896(04)75518-0

Cited by 26 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported survival rates in stages IIIA (14.1%), IIIB (4.6%) and IV (4.2%) are closely comparable to those reported from other centers for IIIA (8–11%), IIIB (1–5%) and IV (1–5%) (3–5). …”

Section: Discussionsupporting

confidence: 86%

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Özkaya

Fındık

Dirican

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Limited data exist concerning the long-term (≥5 year) survival rates of patients with stage IIIB and IV non-small cell lung carcinoma (NSCLC) receiving chemotherapy. We aimed to determine the long-term results of cisplatin plus third-generation (vinorelbine or gemcitabine) cytotoxic chemotherapy in patients with locally advanced and advanced NSCLC. The study included 141 patients, and all patients were followed up from the time of diagnosis until death. The median age of the patients was 59.1±9.9 years. The male-to-female ratio was 124/17; 62.4% of the patients had stage IIIB and 37.6% had stage IV NSCLC. Squamous cell carcinoma, adenocarcinoma and undifferentiated NSCLC subtypes accounted for 69.5, 17.7 and 12.7% of the cases, respectively. The overall response rate was 32.6% and the median survival time was 12.3 months (95% CI, 10.2–14.5). The median survival times for stages IIIB and IV were 12.6±1.4 and 11.9±1.7 months, respectively. The 1-, 2-, 3- and 5-year survival rates were 33, 7.5, 4.3 and 2.8%, respectively. In conclusion, cisplatin-based new-generation cytotoxic agents for combined modality therapy offer an increased hope of long-term survival for patients with locally advanced and advanced NSCLC.

show abstract

Section: Discussionsupporting

confidence: 86%

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Özkaya

Fındık

Dirican

et al. 2012

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…In several retrospective studies [ 27 , 28 ], univariate analysis showed that survival times could be improved when both the primary lung tumor and brain metastases were resected, thus removal of the primary site and SBM appears to be an effective treatment for long-term survival. The American National Cancer Institute reported that the 5-year survival rates of patients with stage IIIA, IIIB, and IV disease were 14%, 5%, and 1%, respectively, and other studies have also reported similar 5-year survival rates for stages IIIB and IV (1–5%) [ 29 , 30 ]. In this study, sub-analysis of the surgery group showed that patients who received resection of both primary and metastasis lesion had a high 5-year survival rate (up to 21%), which is significantly higher than that of stage IIIA.…”

Section: Discussionmentioning

confidence: 99%

Patients with Single Brain Metastasis from Non-Small Cell Lung Cancer Equally Benefit from Stereotactic Radiosurgery and Surgery: A Systematic Review

et al. 2015

View full text Add to dashboard Cite

BackgroundThe appropriate treatment of non-small cell lung cancer (NSCLC) with single brain metastasis (SBM) is still controversial. A systematic review was designed to evaluate the effectiveness of neurosurgery and stereotactic radiosurgery (SRS) in patients with SBM from NSCLC.Material/MethodsPUBMED, EMBASE, the Cochrane Library, Web of Knowledge, Current Controlled Trials, Clinical Trials, and 2 conference websites were searched to select NSCLC patients with only SBM who received brain surgery or SRS. SPSS 18.0 software was used to analyze the mean median survival time (MST) and Stata 11.0 software was used to calculate the overall survival (OS).ResultsA total of 18 trials including 713 patients were systematically reviewed. The MST of the patients was 12.7 months in surgery group and 14.85 months in SRS group, respectively. The 1, 2, and 5 years OS of the patients were 59%, 33%, and 19% in surgery group, and 62%, 33%, and 14% in SRS group, respectively. Furthermore, in the surgery group, the 1 and 3 years OS were 68% and 15% in patients with controlled primary tumors, and 50% and 13% in the other patients with uncontrolled primary tumors, respectively. Interestingly, the 5-year OS was up to 21% in patients with controlled primary tumors.ConclusionsThere was no significant difference in MST or OS between patients treated with neurosurgery and SRS. Patients with resectable lung tumors and SBM may benefit from the resection of both primary lesions and metastasis.

show abstract

“…[ 1 ] According to incomplete statistics, LC-related deaths account for nearly 29% of total cancer-related deaths annually. [ 2 – 4 ] The 5-year survival rate of LC patients is less than 15%. [ 5 , 6 ] Early diagnosis is key for the survival of LC patients.…”

Section: Introductionmentioning

confidence: 99%

SIRT3 acts as a novel biomarker for the diagnosis of lung cancer

Feng¹,

Gu²,

Li³

et al. 2021

Medicine

View full text Add to dashboard Cite

Lung cancer (LC) is a prevalent malignancy worldwide with increased morbidity and mortality. Mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-3 (SIRT3) has been reported to be involved in tumorigenesis. In this retrospective study, we measured the expression and diagnostic value of SIRT3 in LC patients. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to measure serum SIRT3 mRNA level in 150 LC patients and 52 healthy volunteers. SIRT3 protein level was detected using western blot for 84 pairs of LC and adjacent normal tissues. The association of SIRT3 mRNA level with clinical parameters of LC patients was estimated via chi-square test. Receiver operating characteristic curve (ROC) was plotted to evaluate the diagnostic performance of serum SIRT3 in LC patients. SIRT3 mRNA and protein levels were significantly decreased in LC tissues and serum samples, compared with corresponding controls ( P < .05). Moreover, the expression of SIRT3 mRNA was negatively associated with tumor size ( P = .002), tumor node metastasis stage ( P < .001), and metastasis ( P < .001). ROC curve demonstrated that serum SIRT3 could distinguish LC patients from healthy individuals, with an area under the curve of 0.918. The optimal cutoff value was 3.12, reaching a sensitivity of 86.4%, and a specificity of 94%. SIRT3 expression is significantly down-regulated in LC serum and tissues. SIRT3 may be employed as a promising biomarker in the early diagnosis of LC.

show abstract

Supervivencia global a largo plazo en el cáncer de pulmón. Análisis de una serie de 610 pacientes no seleccionados

Cited by 26 publications

References 14 publications

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

Patients with Single Brain Metastasis from Non-Small Cell Lung Cancer Equally Benefit from Stereotactic Radiosurgery and Surgery: A Systematic Review

SIRT3 acts as a novel biomarker for the diagnosis of lung cancer

Contact Info

Product

Resources

About